EP Lab Digest Features Physician Experience with BioSig’s Cardiac Signal Acquisition Technology

EP Lab Digest Features Physician Experience with BioSig’s Cardiac Signal Acquisition Technology

Westport, CT, April 08, 2021 (GLOBE NEWSWIRE) —

  • Main {industry} publication highlights the rising significance of intracardiac indicators in complicated cardiac ablations that deal with irregular coronary heart rhythm issues
  • Excessive-quality intracardiac indicators are deemed important to find out ablation endpoints
  • PURE EP™’s indicators are described as ‘indispensable’ by the doctor consumer

BioSig Applied sciences, Inc. (Nasdaq: BSGM) (“BioSig” or the “Firm”), a medical expertise firm commercializing an modern sign processing platform designed to enhance sign constancy and uncover the complete vary of ECG and intra-cardiac indicators, in the present day introduced the PURE EP™ System was highlighted in a characteristic interview for the April concern of EP Lab Digest, a number one {industry} publication for electrophysiology professionals.

EP Lab Digest interviewed Deepak Gaba, MD, medical electrophysiologist, and Shari Slyder, BS, RT, Managing Director of Cardiovascular Companies, who at present use the PURE EP™ System at Memorial Hospital in South Bend, Indiana. The characteristic interview titled ‘Improved Intracardiac Sign Visualization Throughout RF and Cryo Procedures’ highlighted the rising significance of intracardiac indicators in complicated ablations and the method of incorporating the PURE EP™ System into the follow at Memorial Hospital that conducts 480 EP circumstances yearly.

In line with Dr. Gaba and Mrs. Slyder, the flexibility to precisely discern native and far-field electrograms is crucial for figuring out arrhythmia substrate and guiding ablation endpoints. As the brand new high-density catheters and superior electrode designs enter the market, there’s a renewed deal with buying and displaying high-fidelity intracardiac indicators. Dr. Gaba, who, alongside together with his colleagues, has carried out greater than twenty-five procedures utilizing PURE EP™ to this point, describes the superior high quality of PURE EP™ indicators in numerous medical eventualities utilizing each Cryo and radiofrequency power. Dr. Gaba additional highlights that the indicators acquired with the PURE EP™ System have an effect on his choices about arrhythmia’s origination and optimum website of power supply. Moreover, Shari Slyder, an authorized radiologic technician (AART), elaborates on the benefits of PURE EP™’s superior noise shielding capabilities—a singular characteristic of its proprietary structure. Learn the complete article right here.

“As we proceed increasing our medical footprint, we’re quickly studying how the cardiac info offered by PURE EP™ enhances different applied sciences and elevates the expertise within the electrophysiology lab. The rising doctor acceptance of our expertise is a results of our dedication to addressing unmet medical wants. We’re happy to see the elevated {industry}’s deal with the significance of high-fidelity intracardiac indicators throughout all forms of cardiac arrhythmias,” commented Olivier Chaudoir, Senior Director of Advertising and marketing at BioSig Applied sciences, Inc.

 The PURE EP™ System is being utilized in all forms of arrhythmia circumstances, together with atrial fibrillation, ventricular tachycardia, and atrial flutter. Greater than 680 affected person circumstances have been performed with the expertise to this point. The Firm continues to build up vital quantities of information to be utilized within the new product growth to enrich the PURE EP™ System, together with AI- and machine learning-powered purposes and modules for electrophysiology.

The article is the most recent interview in a sequence of publications that includes BioSig’s PURE EP™ System in industry-leading media retailers. Earlier publications embrace a January 2021 editorial by EP Lab Digest’s Editor-in-Chief, Bradley P. Knight, M.D., FACC, FHRS, a December 2020 characteristic interview with Rafaelle Corbisiero, M.D. and Pedram Kazemian, M.D. of Deborah Coronary heart and Lung Heart, and an April 2020 interview with Andrea Natale, M.D. of Texas Cardiac Arrhythmia Institute at St. David’s Medical Heart.

About BioSig Applied sciences
BioSig Applied sciences is a medical expertise firm commercializing a proprietary biomedical sign processing platform designed to enhance sign constancy and uncover the complete vary of ECG and intra-cardiac indicators (www.biosig.com).

The Firm’s first product, PURE EP™ System, is a computerized system supposed for buying, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac indicators for sufferers present process electrophysiology (EP) procedures in an EP laboratory.

Ahead-looking Statements
This press launch accommodates “forward-looking statements.” Such statements could also be preceded by the phrases “intends,” “might,” “will,” “plans,” “expects,” “anticipates,” “initiatives,” “predicts,” “estimates,” “goals,” “believes,” “hopes,” “potential” or related phrases. Ahead- trying statements aren’t ensures of future efficiency, are based mostly on sure assumptions and are topic to numerous identified and unknown dangers and uncertainties, lots of that are past the Firm’s management, and can’t be predicted or quantified and consequently, precise outcomes might differ materially from these expressed or implied by such forward-looking statements. Such dangers and uncertainties embrace, with out limitation, dangers and uncertainties related to (i) the geographic, social and financial impression of COVID-19 on our capability to conduct our enterprise and lift capital sooner or later when wanted, (ii) our incapability to fabricate our merchandise and product candidates on a industrial scale on our personal, or in collaboration with third events; (iii) difficulties in acquiring financing on commercially cheap phrases; (iv) modifications within the dimension and nature of our competitors; (v) lack of a number of key executives or scientists; and (vi) difficulties in securing regulatory approval to market our merchandise and product candidates. Extra detailed details about the Firm and the danger components that will have an effect on the belief of forward-looking statements is about forth within the Firm’s filings with the Securities and Trade Fee (SEC), together with the Firm’s Annual Report on Type 10-Okay and its Quarterly Studies on Type 10-Q. Traders and safety holders are urged to learn these paperwork freed from cost on the SEC’s web site at http://www.sec.gov. The Firm assumes no obligation to publicly replace or revise its forward-looking statements because of new info, future occasions or in any other case.

CONTACT: Andrew Ballou
BioSig Applied sciences, Inc. 
Vice President, Investor Relations 
54 Wilton Highway, 2nd flooring
Westport, CT 06880
[email protected]
203-409-5444, x133


GlobeNewswire
Newest posts by GlobeNewswire (see all)

— to forextv.com

Leave a Reply

Your email address will not be published. Required fields are marked *